-
Dr. Peter Reiss: Moving Towards the Fourth “90” Goal – Strategies for Improving the Quality of Life and Management of HIV/AIDS Patients
Honorary Dr. at the Amsterdam University Medical Center, University of Amsterdam, former President of the European AIDS Clinical Society (EACS) (2008-2012), former Regional Director for Europe and Central Asia on the Governing Council of the International AIDS Society (IAS) (2006-2014), Co-Chair of the 22nd International AIDS Conference (AIDS 2018), Director of the Netherlands HIV Monitoring…
-
Dr. Linghua Li: Breakthrough on Hepatitis B Cure in HIV/HBV Co-Infected Patients
The 8th Asia-Pacific AIDS and Co-infection Conference (APACC 2023) was held in Singapore from June 8 to 10, 2023. During this conference, an oral presentation (Abstract #9) conducted by Dr. Linghua Li’s team from the Eighth Affiliated Hospital, Guangzhou Medical University, China, attracted significant attention. Dr. Li ‘s team, based on the latest findings from…
-
Dr. Reena Rajasuriar: Eliminating Regional Disparities to Achieve the 2030 End of HIV Epidemic
Co-President of APACC 2023, Chief Researcher at the Center of Excellence for HIV/AIDS Research (CERiA) at the University of Malaya, Associate Professor at the Faculty of Medicine, University of Malaya, Research Fellow at the Peter Doherty Institute for Infection and Immunity, University of Melbourne. She is primarily responsible for the University of Malaya’s HIV Immunology…
-
Dr. Junqi Niu’s Team: Revealing Changes in Human Hepatic Stellate Cells, Discovering Potential Diagnostic and Therapeutic Targets for Liver Fibrosis
Liver cirrhosis is a prevalent condition worldwide, closely associated with the progression of chronic liver diseases and a critical precursor to liver cell carcinoma. Due to its insidious onset and…
-
Youth Forum of APACC 2023 | (5R)-5-hydroxytriptolide Holds Promise for HIV immunological Non-responders Receiving ART
Hello everyone, I’m Xiaosheng Liu , a graduate student from Professor Taisheng Li’s team of Peking Union Medical College Hospital, China. My primary research focus is on the mechanisms underlying immunological non-response in HIV/AIDS patients after long-term antiviral therapy and the development of therapeutic drugs for this condition. I’m delighted to participate in this year’s…
-
Dr. Deborah Donnell: A new long-acting PrEP regimen holds promise to transform the landscape of HIV prevention.
In 2021, the United Nations set forth the goal of “ending the AIDS epidemic by 2030”. To achieve this, not only must countries strengthen the diagnosis and treatment of HIV infections, but they also need to prioritize prevention to minimize the emergence of new infections. Pre-Exposure Prophylaxis (PrEP) long-acting regimens have become a recent focal…
-
IAS 2023 | What are the sequelae of MPOX? Does HIV increase the risk of hospitalization due to MPOX?
The 12th International AIDS Association HIV Science Conference (IAS 2023) was held in Brisbane, Australia from July 23 to 26, 2023. In the oral reports of the conference, experts from the World Health Organization (WHO) reported that global monitoring data for MPOX in 2022 showed that half of the patients with MPOX were HIV carriers.…
-
IAS 2023 | South African study indicates that HIV male patients have a greater likelihood of achieving virological remission than females.
In the recent 12th International AIDS Society (IAS) HIV Science Conference (IAS 2023), a research study from South Africa found that, despite seldom adhering to antiretroviral therapy (ART), 5 male children who were born with HIV still maintained undetectable viral loads. Researchers believe that due to innate immunological gender differences, boys might have a better…
Connecting Medical Expertise through Media